Skip to main content

Advertisement

SpringerLink
Log in

Considerations and Current Trends in the Management of the Geriatric Patient on a Consultation–Liaison Service

  • Geriatric Disorders (JA Cheong, Section Editor)
  • Published:
Current Psychiatry Reports Aims and scope Submit manuscript

Abstract

Purpose of Review

To provide consultation–liaison psychiatrists with an updated resource that can assist in the treatment and management of geriatric patients.

Recent Findings

The current available literature has not shown any differences in efficacy between haloperidol and second-generation antipsychotics in patients with delirium. When considering relative advantages of forms of antipsychotic administration, there is no support for a superior safety profile of oral compared to intramuscular or intravenous administration. A recent meta-analysis of four randomized controlled trials concluded that when melatonin was administered to older age patients on medical wards, it significantly prevented the incidence of delirium when compared with the control group. While suvorexant administered nightly to elderly patients in acute care settings may lower the incidence of delirium, larger studies are needed to confirm this finding. Despite the black box warning of increased mortality risk in older patients with dementia, antipsychotics may be used with caution by the consultation–liaison (CL) psychiatrist to treat the neuropsychologic symptoms of dementia including hallucinations and psychosis in the hospital setting. While antidepressant studies have focused primarily on citalopram and escitalopram in the treatment of agitation in the setting of dementia, these two medications have not been adequately compared directly to other SSRIs for this condition. It is therefore not clear whether citalopram and escitalopram are more efficacious in treating agitation in the setting of dementia when compared to other SSRIs. While the evidence supporting trazodone’s use is limited, it is generally well tolerated and is an option as a PRN for irritability and agitation in patients with Alzheimer’s and mixed dementia. While there is some evidence to support the use of acetylcholinesterase inhibitors for treating cognitive impairments and hallucinations in Lewy body dementia, the usefulness of these agents in other forms of dementia is not well studied, and those studies did not show any benefit in the management of acute agitation. It is important to note that memantine can cause or exacerbate agitation and may be the cause of behavioral dysregulation. There is no evidence to support the routine use of benzodiazepines for behavioral improvement in patients with dementia. Escitalopram and citalopram do have a unique pharmacokinetic properties in the sense that they have been found to have 50–56% plasma protein binding, compared to sertraline, fluoxetine, and paroxetine (95% or more). Pooled analyses suggest that antidepressants are more effective than placebo in reducing the symptoms of post-stroke depression. SSRIs are considered first-line antidepressants in stroke patients, who are often elderly with underlying cardiovascular problems. Although treatment with SSRIs is recommended for post-stroke depression, there are no studies providing conclusive data on the superiority of a specific drug. Older age is associated with a better outcome from ECT, with remission rates of approximately 73% to 90% in patients over 65 years. ECT is the treatment of choice for patients with psychotic depression, and elderly patients with psychotic depression have been shown to have a higher remission rate and faster time to response than depressed patients without psychotic symptoms.

Summary

With the average life expectancy increase, it is projected that 19 million people will reach the age of 85 or higher, an increase from 5.5 million in 2010. With an increasing older population, psychiatric consultation in the management of geriatric patients is becoming more necessary. Psychiatrists must be aware of the unique considerations in elderly patients. In this article, we provide evidence-based guidance to the CL psychiatrist on major issues relating to the older age patient, highlighting recent trends in treatment. First, we provide background on the evaluation of the medically hospitalized geriatric patient. As rates of medical and psychiatric illnesses increase with advancing age, elderly patients are more likely to be taking a higher number of medications as compared to younger patients, and physicians must pay special attention to polypharmacy, including side effects and drug interactions in this group. Next, we focus on the diagnosis, management, and unique needs of the geriatric patient presenting with common clinical syndromes of delirium, dementia, and depression. Delirium and dementia are among the most common causes of cognitive impairment in clinical settings yet are often either unrecognized or misdiagnosed as they may have similar signs and symptoms. In addition, depression is prevalent in older adults, especially in those with comorbid medical illness. Depression can be fatal as the rates of suicide are higher in later life than in any other age group. Consultation can improve the management of elderly patients and prevent unnecessary nursing home placement.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Stern TA, Fricchione GL, Cassem NH, Jellinke MS, Rosenbaum JF. Massachusetts general hospital handbook of general hospital psychiatry. 6th ed. Philadelphia, PA: Saunders, Elsevier; 2010.

  2. Hybels C, Blazer D. Demography and epidemiology of psychiatric disorders in late life. In: Steffens D, Blazer D, Thakur M, editors. The American Psychiatric Publishing Textbook of Geriatric Psychiatry. Fifth ed. Arlington, VA: American Psychiatric Publishing; 2015. p. 22209–3901.

    Google Scholar 

  3. Barnett K, Mercer SW, Norbury M, Watt G, Wyke S, Guthrie B. Epidemiology of multimorbidity and implications for health care, research, and medical education: a cross-sectional study. Lancet. 2012;380(9836):37–43.

    Article  PubMed  Google Scholar 

  4. Ng TP, Feng L, Chiam PC, Kua EH. Psychiatric morbidity and acute hospitalization in elderly people. Int Psychogeriatr. 2006;18(4):701–11.

    Article  PubMed  Google Scholar 

  5. Brahma DK, Wahlang JB, Marak MD, Ch Sangma M. Adverse drug reactions in the elderly. J Pharmacol Pharmacother. 2013;4(2):91–4.

    Article  PubMed  PubMed Central  Google Scholar 

  6. Levenson JL. The American Psychiatric Association Publishing textbook of psychosomatic medicine and consultation-liaison psychiatry. Third ed. Washington, D.C.: American Psychiatric Association Publishing; 2018.

    Book  Google Scholar 

  7. Fountoulakis KN, O'Hara R, Iacovides A, Camilleri CP, Kaprinis S, Kaprinis G, et al. Unipolar late-onset depression: a comprehensive review. Ann Gen Hosp Psychiatry. 2003;2(1):11.

  8. Nardone R, Holler Y, Storti M, Christova M, Tezzon F, Golaszewski S, et al. Thiamine deficiency induced neurochemical, neuroanatomical, and neuropsychological alterations: a reappraisal. ScientificWorldJournal. 2013;2013:309143.

    Article  PubMed  PubMed Central  Google Scholar 

  9. Mikkelsen K, Stojanovska L, Apostolopoulos V. The effects of vitamin B in depression. Curr Med Chem. 2016;23(38):4317–37.

    Article  PubMed  CAS  Google Scholar 

  10. Hermida AP, Janjua AU, Glass OM, Vaughan CP, Goldstein F, Trotti LM, et al. A case of lithium-induced parkinsonism presenting with typical motor symptoms of Parkinson’s disease in a bipolar patient. Int Psychogeriatr. 2016;28(12):2101–4.

  11. Hijazi Z, Lange P, Watson R, Maier AB. The use of cerebral imaging for investigating delirium aetiology. Eur J Intern Med. 2018;52:35–9.

    Article  PubMed  Google Scholar 

  12. Olszewska DA, Costello DJ. Assessment of the usefulness of magnetic resonance brain imaging in patients presenting with acute seizures. Ir J Med Sci. 2014;183(4):621–4.

    Article  PubMed  CAS  Google Scholar 

  13. Lovblad KO, Altrichter S, Mendes Pereira V, Vargas M, Marcos Gonzalez A, Haller S, et al. Imaging of acute stroke: CT and/or MRI. J Neuroradiol. 2015;42(1):55–64.

    Article  PubMed  Google Scholar 

  14. Tombaugh TN, McIntyre NJ. The mini-mental state examination: a comprehensive review. J Am Geriatr Soc. 1992;40(9):922–35.

    Article  PubMed  CAS  Google Scholar 

  15. Smith T, Gildeh N, Holmes C. The Montreal Cognitive Assessment: validity and utility in a memory clinic setting. Can J Psychiatr. 2007;52(5):329–32.

    Article  Google Scholar 

  16. •• Fisher TJ, Schwartz AC, Greenspan HN, Heinrich TW. Dementia: a complex disease with multiple etiologies and multiple treatments. Int J Psychiatry Med. 2016;51(2):171–81. This article discusses practical methods for monitoring the progression of dementia.

    Article  PubMed  Google Scholar 

  17. Irwin SA, Pirrello RD, Hirst JM, Buckholz GT, Ferris FD. Clarifying delirium management: practical, evidenced-based, expert recommendations for clinical practice. J Palliat Med. 2013;16(4):423–35.

    Article  PubMed  PubMed Central  Google Scholar 

  18. Downing LJ, Caprio TV, Lyness JM. Geriatric psychiatry review: differential diagnosis and treatment of the 3 D’s - delirium, dementia, and depression. Curr Psychiatry Rep. 2013;15(6):365.

    Article  PubMed  Google Scholar 

  19. Milton JC, Hill-Smith I, Jackson SH. Prescribing for older people. BMJ (Clin Res Ed). 2008;336(7644):606–9.

    Article  Google Scholar 

  20. Frank C. Pharmacologic treatment of depression in the elderly. Can Fam Physician. 2014;60(2):121–6.

    PubMed  PubMed Central  Google Scholar 

  21. Inouye SK, Westendorp RG, Saczynski JS. Delirium in elderly people. Lancet. 2014;383(9920):911–22.

    Article  PubMed  Google Scholar 

  22. Schwartz AC, Fisher TJ, Greenspan HN, Heinrich TW. Pharmacologic and nonpharmacologic approaches to the prevention and management of delirium. Int J Psychiatry Med. 2016;51(2):160–70.

    Article  PubMed  Google Scholar 

  23. van Velthuijsen EL, Zwakhalen SMG, Mulder WJ, Verhey FRJ, Kempen G. Detection and management of hyperactive and hypoactive delirium in older patients during hospitalization: a retrospective cohort study evaluating daily practice. Int J Geriatr Psychiatry. 2018;33(11):1521–9.

    Article  PubMed  Google Scholar 

  24. Morandi A, Di Santo SG, Cherubini A, Mossello E, Meagher D, Mazzone A, et al. Clinical features associated with delirium motor subtypes in older inpatients: results of a multicenter study. Am J Geriatr Psychiatry. 2017;25(10):1064–71.

    Article  PubMed  Google Scholar 

  25. Wei LA, Fearing MA, Sternberg EJ, Inouye SK. The Confusion Assessment Method: a systematic review of current usage. J Am Geriatr Soc. 2008;56(5):823–30.

    Article  PubMed  PubMed Central  Google Scholar 

  26. Brown TM. Drug-induced delirium. Semin Clin Neuropsychiatry. 2000;5(2):113–24.

    PubMed  CAS  Google Scholar 

  27. Markowitz JD, Narasimhan M. Delirium and antipsychotics: a systematic review of epidemiology and somatic treatment options. Psychiatry (Edgmont). 2008;5(10):29–36.

    Google Scholar 

  28. Gilmore ML, Wolfe DJ. Antipsychotic prophylaxis in surgical patients modestly decreases delirium incidence--but not duration--in high-incidence samples: a meta-analysis. Gen Hosp Psychiatry. 2013;35(4):370–5.

    Article  PubMed  Google Scholar 

  29. Schrijver EJ, de Vries OJ, Verburg A, de Graaf K, Bet PM, van de Ven PM, et al. Efficacy and safety of haloperidol prophylaxis for delirium prevention in older medical and surgical at-risk patients acutely admitted to hospital through the emergency department: study protocol of a multicenter, randomised, double-blind, placebo-controlled clinical trial. BMC Geriatr. 2014;14:96.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  30. Neufeld KJ, Yue J, Robinson TN, Inouye SK, Needham DM. Antipsychotic medication for prevention and treatment of delirium in hospitalized adults: a systematic review and meta-analysis. J Am Geriatr Soc. 2016;64(4):705–14.

    Article  PubMed  PubMed Central  Google Scholar 

  31. •• Maldonado JR. Acute brain failure: pathophysiology, diagnosis, management, and sequelae of delirium. Crit Care Clin. 2017;33(3):461–519. This reference discusses the similar efficacy shared between haloperidol and second-generation antipsychotics in patients with delirium.

    Article  PubMed  Google Scholar 

  32. Narang P, El-Refai M, Parlapalli R, Danilov L, Manda S, Kaur G, et al. Antipsychotic drugs: sudden cardiac death among elderly patients. Psychiatry (Edgmont). 2010;7(10):25–9.

    Google Scholar 

  33. Meyer-Massetti C, Cheng CM, Sharpe BA, Meier CR, Guglielmo BJ. The FDA extended warning for intravenous haloperidol and torsades de pointes: how should institutions respond? J Hosp Med. 2010;5(4):E8–16.

    Article  PubMed  Google Scholar 

  34. Oh ES, Fong TG, Hshieh TT, Inouye SK. Delirium in older persons: advances in diagnosis and treatment. JAMA. 2017;318(12):1161–74.

    Article  PubMed  PubMed Central  Google Scholar 

  35. Bakken MS, Schjott J, Engeland A, Engesaeter LB, Ruths S. Antipsychotic drugs and risk of hip fracture in people aged 60 and older in Norway. J Am Geriatr Soc. 2016;64(6):1203–9.

    Article  PubMed  Google Scholar 

  36. Stroup TS, Gray N. Management of common adverse effects of antipsychotic medications. World Psychiatry. 2018;17(3):341–56.

    Article  PubMed  PubMed Central  Google Scholar 

  37. Tisdale JE, Rasty S, Padhi ID, Sharma ND, Rosman H. The effect of intravenous haloperidol on QT interval dispersion in critically ill patients: comparison with QT interval prolongation for assessment of risk of Torsades de Pointes. J Clin Pharmacol. 2001;41(12):1310–8.

    Article  PubMed  CAS  Google Scholar 

  38. Attard A, Ranjith G, Taylor D. Delirium and its treatment. CNS Drugs. 2008;22(8):631–44.

    Article  PubMed  CAS  Google Scholar 

  39. Lonergan E, Luxenberg J, Areosa Sastre A, Wyller TB. Benzodiazepines for delirium. Cochrane Database Syst Rev. 2009;1:CD006379.

    Google Scholar 

  40. Zaal IJ, Devlin JW, Hazelbag M, Klein Klouwenberg PM, van der Kooi AW, Ong DS, et al. Benzodiazepine-associated delirium in critically ill adults. Intensive Care Med. 2015;41(12):2130–7.

  41. Fong TG, Tulebaev SR, Inouye SK. Delirium in elderly adults: diagnosis, prevention and treatment. Nat Rev Neurol. 2009;5(4):210–20.

    Article  PubMed  PubMed Central  Google Scholar 

  42. Bellapart J, Boots R. Potential use of melatonin in sleep and delirium in the critically ill. Br J Anaesth. 2012;108(4):572–80.

    Article  PubMed  CAS  Google Scholar 

  43. Artemiou P, Bily B, Bilecova-Rabajdova M, Sabol F, Torok P, Kolarcik P, et al. Melatonin treatment in the prevention of postoperative delirium in cardiac surgery patients. Kardiochir Torakochirurgia Pol. 2015;12(2):126–33.

  44. • Chen S, Shi L, Liang F, Xu L, Desislava D, Wu Q, et al. Exogenous melatonin for delirium prevention: a meta-analysis of randomized controlled trials. Mol Neurobiol. 2016;53(6):4046–53. This study presents evidence supporting the use of melatonin to prevent delirium in high-risk older age patients.

    Article  PubMed  CAS  Google Scholar 

  45. Inoue T, Morita M, Wada A, Kasai K, Kondo S. A case of persistent delirium resolved promptly with suvorexant. Prim Care Companion CNS Disord. 2017;19(2).

  46. Hatta K, Kishi Y, Wada K, Takeuchi T, Ito S, Kurata A, et al. Preventive effects of suvorexant on delirium: a randomized placebo-controlled trial. J Clin Psychiatry. 2017.

  47. Masuyama T, Sanui M, Yoshida N, Iizuka Y, Ogi K, Yagihashi S, et al. Suvorexant is associated with a low incidence of delirium in critically ill patients: a retrospective cohort study. Psychogeriatrics : the official journal of the Japanese Psychogeriatric Society. 2018;18(3):209–15.

  48. Hugo J, Ganguli M. Dementia and cognitive impairment: epidemiology, diagnosis, and treatment. Clin Geriatr Med. 2014;30(3):421–42.

    Article  PubMed  PubMed Central  Google Scholar 

  49. Hope T, Keene J, Fairburn C, McShane R, Jacoby R. Behaviour changes in dementia. 2: are there behavioural syndromes? Int J Geriatr Psychiatry. 1997;12(11):1074–8.

    Article  PubMed  CAS  Google Scholar 

  50. Kales HC, Gitlin LN, Lyketsos CG. Management of neuropsychiatric symptoms of dementia in clinical settings: recommendations from a multidisciplinary expert panel. J Am Geriatr Soc. 2014;62(4):762–9.

    Article  PubMed  PubMed Central  Google Scholar 

  51. Fong TG, Davis D, Growdon ME, Albuquerque A, Inouye SK. The interface between delirium and dementia in elderly adults. Lancet Neurol. 2015;14(8):823–32.

    Article  PubMed  PubMed Central  Google Scholar 

  52. Gustafsson M, Karlsson S, Gustafson Y, Lövheim H. Psychotropic drug use among people with dementia--a six-month follow-up study. BMC Pharmacol Toxicol. 2013;14:56.

    Article  PubMed  PubMed Central  Google Scholar 

  53. Devanand DP, Pelton GH, Cunqueiro K, Sackeim HA, Marder K. A 6-month, randomized, double-blind, placebo-controlled pilot discontinuation trial following response to haloperidol treatment of psychosis and agitation in Alzheimer’s disease. Int J Geriatr Psychiatry. 2011;26(9):937–43.

    Article  PubMed  CAS  Google Scholar 

  54. Dorsey ER, Rabbani A, Gallagher SA, Conti RM, Alexander GC. Impact of FDA black box advisory on antipsychotic medication use. Arch Intern Med. 2010;170(1):96–103.

    Article  PubMed  PubMed Central  Google Scholar 

  55. Kuehn BM. FDA: antipsychotics risky for elderly. JAMA. 2008;300(4):379–80.

    Article  PubMed  CAS  Google Scholar 

  56. Steinberg M, Lyketsos CG. Atypical antipsychotic use in patients with dementia: managing safety concerns. Am J Psychiatry. 2012;169(9):900–6.

    Article  PubMed  PubMed Central  Google Scholar 

  57. Schneider LS, Dagerman KS, Insel P. Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials. JAMA. 2005;294(15):1934–43.

    Article  PubMed  CAS  Google Scholar 

  58. Lonergan E, Luxenberg J, Colford J. Haloperidol for agitation in dementia. Cochrane Database Syst Rev. 2001;(4):Cd002852.

  59. De Deyn PP, Buitelaar J. Risperidone in the management of agitation and aggression associated with psychiatric disorders. Eur Psychiatry. 2006;21(1):21–8.

    Article  PubMed  Google Scholar 

  60. Tampi RR, Tampi DJ, Balachandran S, Srinivasan S. Antipsychotic use in dementia: a systematic review of benefits and risks from meta-analyses. Ther Adv Chronic Dis. 2016;7(5):229–45.

    Article  PubMed  PubMed Central  Google Scholar 

  61. Schneider LS, Tariot PN, Dagerman KS, Davis SM, Hsiao JK, Ismail MS, et al. Effectiveness of atypical antipsychotic drugs in patients with Alzheimer’s disease. N Engl J Med. 2006;355(15):1525–38.

  62. Schneider LS, Dagerman K, Insel PS. Efficacy and adverse effects of atypical antipsychotics for dementia: meta-analysis of randomized, placebo-controlled trials. Am J Geriatr Psychiatry. 2006;14(3):191–210.

    Article  PubMed  Google Scholar 

  63. Porsteinsson AP, Keltz MA, Smith JS. Role of citalopram in the treatment of agitation in Alzheimer’s disease. Neurodegenerative Dis Manag. 2014;4(5):345–9.

    Article  Google Scholar 

  64. Hutton LMJ, Cave AJ, St-Jean R, Banh HL. Should we be worried about QTc prolongation using citalopram? A Review. J Pharm Pract. 2017;30(3):353–8.

    Article  PubMed  Google Scholar 

  65. Do A, Noohi S, Elie D, Mahdanian AA, Yu C, Segal M, et al. Health Canada warning on citalopram and escitalopram--its effects on prescribing in consultation-liaison psychiatry. Psychosomatics. 2016;57(1):57–63.

  66. Drye LT, Spragg D, Devanand DP, Frangakis C, Marano C, Meinert CL, et al. Changes in QTc interval in the citalopram for agitation in Alzheimer’s disease (CitAD) randomized trial. PLoS One. 2014;9(6):e98426.

  67. Carceller-Sindreu M, de Diego-Adelino J, Portella MJ, Garcia-Moll X, Figueras M, Fernandez-Vidal A, et al. Lack of relationship between plasma levels of escitalopram and QTc-interval length. Eur Arch Psychiatry Clin Neurosci. 2017.

  68. Davies SJ, Burhan AM, Kim D, Gerretsen P, Graff-Guerrero A, Woo VL, et al. Sequential drug treatment algorithm for agitation and aggression in Alzheimer’s and mixed dementia. J Psychopharmacol (Oxford, England). 2018;32(5):509–23.

    Article  CAS  Google Scholar 

  69. Lopez-Pousa S, Garre-Olmo J, Vilalta-Franch J, Turon-Estrada A, Pericot-Nierga I. Trazodone for Alzheimer’s disease: a naturalistic follow-up study. Arch Gerontol Geriatr. 2008;47(2):207–15.

    Article  PubMed  CAS  Google Scholar 

  70. Aisen PS, Johannessen DJ, Marin DB. Trazodone for behavioral disturbance in Alzheimer’s disease. Am J Geriatr Psychiatry. 1993;1(4):349–50.

    Article  PubMed  Google Scholar 

  71. Lebert F, Stekke W, Hasenbroekx C, Pasquier F. Frontotemporal dementia: a randomised, controlled trial with trazodone. Dement Geriatr Cogn Disord. 2004;17(4):355–9.

    Article  PubMed  CAS  Google Scholar 

  72. Trinh NH, Hoblyn J, Mohanty S, Yaffe K. Efficacy of cholinesterase inhibitors in the treatment of neuropsychiatric symptoms and functional impairment in Alzheimer disease: a meta-analysis. JAMA. 2003;289(2):210–6.

    Article  PubMed  CAS  Google Scholar 

  73. Tariot PN, Farlow MR, Grossberg GT, Graham SM, McDonald S, Gergel I, et al. Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial. JAMA. 2004;291(3):317–24.

  74. Velayudhan L, Ffytche D, Ballard C, Aarsland D. New therapeutic strategies for Lewy body dementias. Curr Neurol Neurosci Rep. 2017;17(9):68.

    Article  PubMed  CAS  Google Scholar 

  75. Ukai K, Fujishiro H, Iritani S, Ozaki N. Long-term efficacy of donepezil for relapse of visual hallucinations in patients with dementia with Lewy bodies. Psychogeriatrics : the official journal of the Japanese Psychogeriatric Society. 2014.

  76. Da Re F, Rucci F, Isella V. Retrospective study on agitation provoked by memantine in dementia. J Neuropsychiatry Clin Neurosci. 2015;27(1):e10–3.

    Article  PubMed  Google Scholar 

  77. Unutzer J, Simon G, Belin TR, Datt M, Katon W, Patrick D. Care for depression in HMO patients aged 65 and older. J Am Geriatr Soc. 2000;48(8):871–8.

    Article  PubMed  CAS  Google Scholar 

  78. Callahan CM, Hendrie HC, Nienaber NA, Tierney WM. Suicidal ideation among older primary care patients. J Am Geriatr Soc. 1996;44(10):1205–9.

    Article  PubMed  CAS  Google Scholar 

  79. Waern M, Rubenowitz E, Runeson B, Skoog I, Wilhelmson K, Allebeck P. Burden of illness and suicide in elderly people: case-control study. BMJ (Clin Res Ed). 2002;324(7350):1355.

    Article  Google Scholar 

  80. Fiske A, Wetherell JL, Gatz M. Depression in older adults. Annu Rev Clin Psychol. 2009;5:363–89.

    Article  PubMed  PubMed Central  Google Scholar 

  81. Koenig HG, George LK. Depression and physical disability outcomes in depressed medically ill hospitalized older adults. Am J Geriatr Psychiatry. 1998;6(3):230–47.

    Article  PubMed  CAS  Google Scholar 

  82. Muliyala KP, Varghese M. The complex relationship between depression and dementia. Ann Indian Acad Neurol. 2010;13(Suppl 2):S69–73.

    PubMed  PubMed Central  Google Scholar 

  83. Kok RM, Reynolds CF 3rd. Management of depression in older adults: a review. Jama. 2017;317(20):2114–22.

    Article  PubMed  CAS  Google Scholar 

  84. Kang H, Zhao F, You L, Giorgetta C, Venkatesh D, Sarkhel S, et al. Pseudo-dementia: a neuropsychological review. Ann Indian Acad Neurol. 2014;17(2):147–54.

    Article  PubMed  PubMed Central  Google Scholar 

  85. Steffens DC. Late-life depression and the prodromes of dementia. JAMA Psychiatry. 2017;74(7):673–4.

    Article  PubMed  Google Scholar 

  86. Neubauer AB, Wahl HW, Bickel H. Depressive symptoms as predictor of dementia versus continuous cognitive decline: a 3-year prospective study. Eur J Ageing. 2013;10(1):37–48.

    Article  PubMed  Google Scholar 

  87. Franchini L, Serretti A, Gasperini M, Smeraldi E. Familial concordance of fluvoxamine response as a tool for differentiating mood disorder pedigrees. J Psychiatr Res. 1998;32(5):255–9.

    Article  PubMed  CAS  Google Scholar 

  88. Gelhorn HL, Sexton CC, Classi PM. Patient preferences for treatment of major depressive disorder and the impact on health outcomes: a systematic review. Prim Care Companion CNS Disord. 2011;13(5).

  89. Hawton K, Bergen H, Simkin S, Cooper J, Waters K, Gunnell D, et al. Toxicity of antidepressants: rates of suicide relative to prescribing and non-fatal overdose. Br J Psychiatry. 2010;196(5):354–8.

  90. van Harten J. Clinical pharmacokinetics of selective serotonin reuptake inhibitors. Clin Pharmacokinet. 1993;24(3):203–20.

    Article  PubMed  Google Scholar 

  91. Rao N. The clinical pharmacokinetics of escitalopram. Clin Pharmacokinet. 2007;46(4):281–90.

    Article  PubMed  CAS  Google Scholar 

  92. Westenberg HG, Sandner C. Tolerability and safety of fluvoxamine and other antidepressants. Int J Clin Pract. 2006;60(4):482–91.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  93. • Villa RF, Ferrari F, Moretti A. Post-stroke depression: mechanisms and pharmacological treatment. Pharmacol Ther. 2018;184:131–44. This study emphasizes the impact of post-stroke depression on cognitive recovery, functional outcomes, and quality of life.

    Article  PubMed  CAS  Google Scholar 

  94. Chen Y, Patel NC, Guo JJ, Zhan S. Antidepressant prophylaxis for poststroke depression: a meta-analysis. Int Clin Psychopharmacol. 2007;22(3):159–66.

    Article  PubMed  Google Scholar 

  95. Mead GE, Hsieh CF, Hackett M. Selective serotonin reuptake inhibitors for stroke recovery. Jama. 2013;310(10):1066–7.

    Article  PubMed  CAS  Google Scholar 

  96. Xu XM, Zou DZ, Shen LY, Liu Y, Zhou XY, Pu JC, et al. Efficacy and feasibility of antidepressant treatment in patients with post-stroke depression. Medicine. 2016;95(45):e5349.

  97. Paolucci S. Advances in antidepressants for treating post-stroke depression. Expert Opin Pharmacother. 2017;18(10):1011–7.

    Article  PubMed  CAS  Google Scholar 

  98. Esparrago Llorca G, Castilla-Guerra L, Fernandez Moreno MC, Ruiz Doblado S, Jimenez Hernandez MD. Post-stroke depression: an update. Neurologia (Barcelona, Spain). 2015;30(1):23–31. This study provides support for SSRIs as a first-line treatment modality in post-stroke depression.

    Article  CAS  Google Scholar 

  99. Tirmizi O, Raza A, Trevino K, Husain MM. Electroconvulsive therapy: how modern techniques improve patient outcomes: refinements have decreased memory loss, other adverse effects while retaining efficacy: refinements have decreased memory loss, other adverse effects while retaining efficacy. Curr Psychiatr Ther. 2012;11(10):24–46.

    Google Scholar 

  100. •• Hermida AP, Glass OM, Shafi H, McDonald WM. Electroconvulsive therapy in depression: current practice and future direction. Psychiatr Clin North Am. 2018;41(3):341–53. This reference highlights the improved safety and tolerability of ECT in the last several years.

    Article  PubMed  Google Scholar 

  101. Riva-Posse P, Hermida AP, McDonald WM. The role of electroconvulsive and neuromodulation therapies in the treatment of geriatric depression. Psychiatr Clin North Am. 2013;36(4):607–30.

    Article  PubMed  Google Scholar 

  102. O'Connor MK, Knapp R, Husain M, Rummans TA, Petrides G, Smith G, et al. The influence of age on the response of major depression to electroconvulsive therapy: a C.O.R.E. Report. Am J Geriatr Psychiatry. 2001;9(4):382–90.

  103. Petrides G, Fink M, Husain MM, Knapp RG, Rush AJ, Mueller M, et al. ECT remission rates in psychotic versus nonpsychotic depressed patients: a report from CORE. J ECT. 2001;17(4):244–53.

  104. Kellner CH, Fink M, Knapp R, Petrides G, Husain M, Rummans T, et al. Relief of expressed suicidal intent by ECT: a consortium for research in ECT study. Am J Psychiatry. 2005;162(5):977–82.

  105. Fink M, Kellner CH, McCall WV. Optimizing ECT technique in treating catatonia. J ECT. 2016;32(3):149–50.

    Article  PubMed  Google Scholar 

  106. Hermida AP, Tang YL, Glass O, Janjua AU, McDonald WM. Efficacy and safety of ECT for Behavioral and Psychological Symptoms of Dementia (BPSD): a retrospective chart review. Am J Geriatr Psychiatry. 2020;28(2):157–63.

Download references

Author information

Authors and Affiliations

  1. Northeast Georgia Health System, Gainesville, GA, USA

    Oliver M. Glass

  2. Geriatric Psychiatry, Emory University, Atlanta, GA, USA

    Adriana P. Hermida

  3. Department of Psychiatry and Behavioral Sciences, Emory University School of Medicine, Atlanta, GA, USA

    Rachel Hershenberg & Ann C. Schwartz

  4. Treatment Resistant Depression Program, Emory University, Atlanta, GA, USA

    Rachel Hershenberg

  5. Psychiatry Consultation-Liaison Service, Grady Memorial Hospital, 80 Jesse Hill Jr. Dr., Atlanta, GA, USA

    Ann C. Schwartz

Authors
  1. Oliver M. Glass
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Adriana P. Hermida
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Rachel Hershenberg
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Ann C. Schwartz
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ann C. Schwartz.

Ethics declarations

Conflict of Interest

Oliver M. Glass, Adriana P. Hermida, Rachel Hershenberg, and Ann C. Schwartz each declare no potential conflicts of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This article is part of the Topical Collection on Geriatric Disorders

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Glass, O.M., Hermida, A.P., Hershenberg, R. et al. Considerations and Current Trends in the Management of the Geriatric Patient on a Consultation–Liaison Service. Curr Psychiatry Rep 22, 21 (2020). https://doi.org/10.1007/s11920-020-01147-2

Download citation

  • Published:

  • DOI: https://doi.org/10.1007/s11920-020-01147-2

Keywords

Search

Navigation